-
公开(公告)号：US20050277619A1
公开(公告)日：2005-12-15
申请号：US11101807
申请日：2005-04-07
申请人： Qun Dang , Mark Erion , M. Reddy , Edward Robinson , Srinivas Kasibhatla , K. Reddy
发明人： Qun Dang , Mark Erion , M. Reddy , Edward Robinson , Srinivas Kasibhatla , K. Reddy
IPC分类号： A61P3/10 , C07F9/6561 , C07F9/6571 , A61K31/675 , C07F9/6512
CPC分类号： C07F9/65616 , C07F9/657181
摘要： Novel purine compounds of Formula 1, pharmaceutically acceptable prodrugs and salts thereof, and their use as fructose 1,6-bisphosphatase inhibitors.
摘要翻译： 式1的新型嘌呤化合物，其药学上可接受的前药和盐，以及它们作为果糖1,6-二磷酸酶抑制剂的用途。
-
公开(公告)号：US20080015195A1
公开(公告)日：2008-01-17
申请号：US11842035
申请日：2007-08-20
申请人： Qun Dang , Srinivas Kasibhatla , K. Reddy , Mark Erion , M. Reddy , Atul Agarwal
发明人： Qun Dang , Srinivas Kasibhatla , K. Reddy , Mark Erion , M. Reddy , Atul Agarwal
IPC分类号： A61K31/53 , A61K31/33 , A61K31/341 , A61K31/41 , A61K31/4155 , A61K31/4164 , A61K31/421 , A61P3/10 , C07D213/02 , C07D277/62 , C07D277/02 , C07D263/02 , C07D257/04 , C07D253/02 , C07D241/00 , C07D239/00 , C07D233/00 , C07D231/00 , C07D307/02 , C07D293/06 , C07D285/12 , A61P9/00 , A61K31/426 , A61K31/428 , A61K31/433 , A61K31/44 , A61K31/4965 , A61K31/505
CPC分类号： C07F9/4006 , C07F9/5728 , C07F9/58 , C07F9/650952 , C07F9/6512 , C07F9/653 , C07F9/65324 , C07F9/6539 , C07F9/65395 , C07F9/6541 , C07F9/65515 , C07F9/65517 , C07F9/655345 , C07F9/65583 , C07F9/65586 , C07F9/657181 , C07F9/6578 , C07F9/65846
摘要： Novel FBPase inhibitors of the formula I and X are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.
摘要翻译： 式I和X的新型FBPase抑制剂可用于治疗与血糖升高相关的糖尿病和其它病症。
-
公开(公告)号：US20070232571A1
公开(公告)日：2007-10-04
申请号：US11742023
申请日：2007-04-30
申请人： Qun Dang , Srinivas Kasibhatla , K. Reddy , Mark Erion , M. Reddy , Atul Agarwal
发明人： Qun Dang , Srinivas Kasibhatla , K. Reddy , Mark Erion , M. Reddy , Atul Agarwal
CPC分类号： C07F9/4006 , C07F9/5728 , C07F9/58 , C07F9/650952 , C07F9/6512 , C07F9/653 , C07F9/65324 , C07F9/6539 , C07F9/65395 , C07F9/6541 , C07F9/65515 , C07F9/65517 , C07F9/655345 , C07F9/65583 , C07F9/65586 , C07F9/657181 , C07F9/6578 , C07F9/65846
摘要： Novel FBPase inhibitors of the formula I and X are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.
摘要翻译： 式I和X的新型FBPase抑制剂可用于治疗与血糖升高相关的糖尿病和其它病症。
-
公开(公告)号：US20050176684A1
公开(公告)日：2005-08-11
申请号：US11043859
申请日：2005-01-25
申请人： Brett Bookser , Qun Dang , K. Reddy
发明人： Brett Bookser , Qun Dang , K. Reddy
IPC分类号： A61K31/662 , A61P3/10 , A61P43/00 , C07F9/38 , C07F9/6539 , C07F9/655 , C07F9/6553 , C07F9/6558 , A61K31/675
CPC分类号： C07F9/3808 , C07F9/3826 , C07F9/6539 , C07F9/65515 , C07F9/65583 , C07F9/65586
摘要： Novel FBPase inhibitors of the formula I are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.
摘要翻译： 式I的新型FBPase抑制剂可用于治疗与血糖升高相关的糖尿病和其它病症。
-
公开(公告)号：US09650375B2
公开(公告)日：2017-05-16
申请号：US14769159
申请日：2014-03-10
申请人： Merck Sharp & Dohme Corp. , John J. Acton, III , Rajan Anand , Ashok Arasappan , Qun Dang , Iyassu Sebhat , Zhifa Pu , Takao Suzuki
发明人： John J. Acton, III , Rajan Anand , Ashok Arasappan , Qun Dang , Iyassu Sebhat , Zhifa Pu , Takao Suzuki
IPC分类号： C07D209/04 , C07D471/04 , A61K31/404 , C07D209/12 , C07D209/30 , A61K31/366 , A61K31/397 , A61K31/437 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/541 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D405/04 , C07D405/06 , C07D405/10 , C07D413/04 , C07D413/10 , C07D493/04 , C07D209/18 , C07D519/00 , C07D209/08
CPC分类号： C07D471/04 , A61K31/366 , A61K31/397 , A61K31/404 , A61K31/437 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/541 , C07D209/08 , C07D209/12 , C07D209/18 , C07D209/30 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D405/04 , C07D405/06 , C07D405/10 , C07D413/04 , C07D413/10 , C07D493/04 , C07D519/00 , A61K2300/00
摘要： Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.
-
6.发明授权2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases 有权2'-叠氮基取代的核苷衍生物及其用于治疗病毒性疾病的方法公开(公告)号：US09156872B2
公开(公告)日：2015-10-13
申请号：US14111685
申请日：2012-04-11
申请人： Vinay Girijavallabhan , F. George Njoroge , Stephane Bogen , Frank Bennett , Vishal Verma , Ashok Arasappan , Kevin Chen , Ying Huang , Angela Kerekes , Latha Nair , Dmitri Pissarnitski , Qun Dang , Ian Davies , David B. Olsen , Andrew Stamford , Joseph P. Vacca
发明人： Vinay Girijavallabhan , F. George Njoroge , Stephane Bogen , Frank Bennett , Vishal Verma , Ashok Arasappan , Kevin Chen , Ying Huang , Angela Kerekes , Latha Nair , Dmitri Pissarnitski , Qun Dang , Ian Davies , David B. Olsen , Andrew Stamford , Joseph P. Vacca
IPC分类号： C07H19/06 , C07H19/10 , C07H19/12 , C07H19/16 , C07H19/04 , C07H19/20 , C07H19/207 , C07H19/11 , C07H19/213 , A61K31/7056 , A61K31/706 , A61K31/7064 , A61K31/7068 , A61K31/7072 , A61K31/708 , A61K45/06
CPC分类号： C07H19/06 , A61K31/7056 , A61K31/706 , A61K31/7064 , A61K31/7068 , A61K31/7072 , A61K31/708 , A61K45/06 , A61P31/14 , C07H19/10 , C07H19/11 , C07H19/12 , C07H19/16 , C07H19/20 , C07H19/207 , C07H19/213
摘要： The present invention relates to 2′-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Azido Substituted Nucleoside Derivative, and methods of using the 2′-Azido Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
摘要翻译： 本发明涉及式（I）的2'-叠氮基取代的核苷衍生物及其药学上可接受的盐，其中B，X，R 1，R 2和R 3如本文所定义。 本发明还涉及包含至少一种2'-叠氮基取代的核苷衍生物的组合物，以及使用2'-叠氮基取代的核苷衍生物治疗或预防患者HCV感染的方法。
-
公开(公告)号：US09145391B2
公开(公告)日：2015-09-29
申请号：US14116199
申请日：2012-05-04
申请人： Denis Deschenes , Michael D. Altman , John Michael Ellis , Christian Fischer , Andrew M. Haidle , Solomon D. Kattar , Alan B. Northrup , Adam J. Schell , Graham F. Smith , Brandon M. Taoka , Corey Bienstock , Maria Emilia Di Francesco , Anthony Donofrio , Scott Peterson , Kerrie B. Spencer , James Patrick Jewell , Amjad Ali , David Jonathan Bennett , Qun Dang , John Wai
发明人： Denis Deschenes , Michael D. Altman , John Michael Ellis , Christian Fischer , Andrew M. Haidle , Solomon D. Kattar , Alan B. Northrup , Adam J. Schell , Graham F. Smith , Brandon M. Taoka , Corey Bienstock , Maria Emilia Di Francesco , Anthony Donofrio , Scott Peterson , Kerrie B. Spencer , James Patrick Jewell , Amjad Ali , David Jonathan Bennett , Qun Dang , John Wai
IPC分类号： C07D213/73 , C07D401/14 , C07D401/12 , C07D409/14 , C07D417/14 , C07D471/04
CPC分类号： C07D401/14 , C07D401/12 , C07D409/14 , C07D417/14 , C07D471/04
摘要： The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis and cancer.
摘要翻译： 本发明提供了式I的新型嘧啶胺，其是脾脏酪氨酸激酶的有效抑制剂，或其前药，并且可用于治疗和预防由所述酶介导的疾病，例如哮喘，COPD和类风湿性关节炎和癌症。
-
公开(公告)号：US08710236B2
公开(公告)日：2014-04-29
申请号：US13083321
申请日：2011-04-08
申请人： Jorge E. Gomez-Galeno , K. Raja Reddy , Paul D. van Poelje , Robert Huerta Lemus , Thanh Huu Nguyen , Matthew P. Grote , Qun Dang , Scott J. Hecker , Venkat Reddy Mali , Mingwei Chen , Zhili Sun , Serge Henri Boyer , Haiqing Li , William Craigo
发明人： Jorge E. Gomez-Galeno , K. Raja Reddy , Paul D. van Poelje , Robert Huerta Lemus , Thanh Huu Nguyen , Matthew P. Grote , Qun Dang , Scott J. Hecker , Venkat Reddy Mali , Mingwei Chen , Zhili Sun , Serge Henri Boyer , Haiqing Li , William Craigo
IPC分类号： C07D263/57 , C07D307/81 , C07C309/15
CPC分类号： C07C309/15 , C07C307/02 , C07C309/11 , C07C317/44 , C07C323/62 , C07C2601/02 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D209/20 , C07D213/53 , C07D213/75 , C07D235/30 , C07D261/08 , C07D263/56 , C07D277/66 , C07D307/68 , C07D307/81 , C07D317/66 , C07D333/38 , C07D405/04 , C07D409/12 , C07D413/04 , C07D471/04 , C07D498/04
摘要： The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
摘要翻译： 本发明提供具有胰高血糖素受体拮抗剂或反向激动剂活性的新颖的式（I）化合物及其药学上可接受的盐和共晶体。 本发明进一步提供了包含其的药物组合物以及治疗，预防，延迟发病时间或降低其中指示一种或多种胰高血糖素受体拮抗剂的疾病或病症的发展或进展的风险的方法， 包括I型和II型糖尿病，胰岛素抵抗和高血糖。 本发明还提供制备式I化合物的方法，包括其盐和共结晶，以及包含其的药物组合物。
-
公开(公告)号：US20130030029A1
公开(公告)日：2013-01-31
申请号：US13058604
申请日：2009-08-13
申请人： Jorge E. Gomez-Galeno , Scott J. Hecker , Qun Dang , Mali Venkat Reddy , Zhili Sun , Matthew P. Grote , Thanh Huu Nguyen , Robert Huerta Lemus , Haiqing Li
发明人： Jorge E. Gomez-Galeno , Scott J. Hecker , Qun Dang , Mali Venkat Reddy , Zhili Sun , Matthew P. Grote , Thanh Huu Nguyen , Robert Huerta Lemus , Haiqing Li
IPC分类号： A61K31/167 , A61P3/10 , A61K31/423 , C07C309/15 , C07D263/57
CPC分类号： C07C309/15 , A61K31/185 , A61K31/423 , A61K45/06 , C07B2200/07 , C07C2601/14 , C07C2601/16 , C07D263/57
摘要： Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof. Formula I
摘要翻译： 本文提供了具有胰高血糖素受体拮抗剂或反向激动剂活性的化合物，包括其对映体纯的形式及其药学上可接受的盐或共晶体和前药。 此外，本文提供的是包含其的药物组合物以及治疗，预防，延迟发病时间或降低发生或进展一种或多种胰高血糖素受体拮抗剂的疾病或病症的风险的方法，包括 I型和II型糖尿病，胰岛素抵抗和高血糖。 此外，本文提供了制备或制备本文公开的化合物的方法，包括其对映体纯的形式，及其药学上可接受的盐或共晶体和前药。 一级方程式
-
10.发明申请公开(公告)号：US20110263533A1
公开(公告)日：2011-10-27
申请号：US13124898
申请日：2009-10-12
申请人： Qun Dang , Tony S. Gibson , Hongjian Jiang , De Michael Chung , Jianming Bao , Jinlong Jiang , Andy Kassick , Ahmet Kekec , Ping Lan , Huagang Lu , Gergely M. Makara , F. Anthony Romero , Iyassu Sebhat , David Wilson , Dariusz Wodka , Brett C. Bookser
发明人： Qun Dang , Tony S. Gibson , Hongjian Jiang , De Michael Chung , Jianming Bao , Jinlong Jiang , Andy Kassick , Ahmet Kekec , Ping Lan , Huagang Lu , Gergely M. Makara , F. Anthony Romero , Iyassu Sebhat , David Wilson , Dariusz Wodka , Brett C. Bookser
IPC分类号： A61K31/675 , C07F9/40 , C07F9/6574 , A61P35/00 , A61P3/04 , A61P3/06 , A61P9/12 , C07F9/6506 , A61P3/10
CPC分类号： C07F9/65068 , C07F9/65583 , C07F9/657181
摘要： Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, Metabolic Syndrome, obesity, hypercholesterolemia, and hypertension.
摘要翻译： 结构式（I）的新型化合物是AMP-蛋白激酶的活化剂，可用于治疗，预防和抑制AMPK活化蛋白激酶介导的疾病。 本发明的化合物可用于治疗2型糖尿病，高血糖症，代谢综合征，肥胖，高胆固醇血症和高血压。
-
-
-
-
-
-
-
-
-
搜索结果
53 条记录 (耗时 0.072 秒)
